Patrick R Harrington

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment
    Patrick R Harrington
    Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, MD 20993, USA
    Hepatology 55:1048-57. 2012
  2. ncbi request reprint Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways
    Takashi E Komatsu
    Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA Electronic address
    Antiviral Res 101:12-25. 2014

Detail Information

Publications2

  1. ncbi request reprint Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment
    Patrick R Harrington
    Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, MD 20993, USA
    Hepatology 55:1048-57. 2012
    ..Analyses of Phase 2 boceprevir and telaprevir trials indicated subjects with detectable/BLOQ HCV RNA at RGT timepoints benefited from extended treatment duration...
  2. ncbi request reprint Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways
    Takashi E Komatsu
    Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA Electronic address
    Antiviral Res 101:12-25. 2014
    ....